Vir Biotechnology (NASDAQ:VIR) used its latest investor call to outline a new strategic collaboration with Astellas to advance VIR-5500, a PSMA-directed, dual-masked T-cell engager for prostate cancer ...
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, ...
Paulick Report on MSN
‘More Than I Ever Thought I Could Have’: Carlos Santamaria Making The Most Of Second Chance
Trainer Carlos Santamaria knows he was given a second chance via a life-saving kidney transplant in November 2019. Since then, he’s made it his personal mission to turn gratitude into action, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results